A Study to Test a Single Dose of a New Tablet Formulation of TRTL-729

Inclusion criteria

• Generally healthy, ambulatory male or female adults aged 18 to 55 years, as determined by the investigator.
• Able and willing to provide written informed consent and comply with all study procedures and the visit schedule.
• Body Mass Index (BMI) 18.0 to 32.0 kilograms per meter square kg/m^2 and body weight greater than (>)50 kilograms (kg).
• Clinically acceptable medical history, physical examination, vital signs, clinical laboratory tests, and 12-lead electrocardiogram (ECG), as determined by the investigator.
• QT interval Corrected using Fridericia's Formula (QTcF) lesser than or equal to (≤)450 milliseconds (msec) for males or ≤470 msec for females.
• Nonsmokers or light smokers (less than [<]10 cigarettes/week or equivalent vaping) for at least 3 months before dosing and willing to abstain during confinement.
• Females must be of nonchildbearing potential or, if of childbearing potential, must have a negative pregnancy test and agree to use highly effective contraception throughout the required study period.
• Male participants must agree to use appropriate contraception and refrain from sperm donation for the required study period.

Exclusion criteria

• Any clinically significant acute or chronic medical condition that, in the investigator's opinion, could affect participant safety or study assessments.
• History of seizures, epilepsy, significant head injury associated with loss of consciousness, family history of seizures or epilepsy, or other conditions or medications that increase seizure risk.
• Clinically significant cardiovascular, cerebrovascular, or peripheral vascular disease, clinically significant ECG abnormalities, torsade de pointes, or a family history of long QT syndrome or sudden cardiac death.
• Active infection or clinically significant recent illness before screening or dosing.
• Positive test for Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C.
• Clinically significant hepatic or renal impairment or clinically significant laboratory abnormalities.
• History of malignancy within the past 10 years (except adequately treated nonmetastatic basal cell or squamous cell skin cancer or cervical carcinoma in situ).
• Current or recent substance or alcohol use disorder, or positive drug or alcohol screening.
• Current or history of clinically significant psychiatric illness, or suicidal ideation or behavior
• Pregnant, breastfeeding, or planning pregnancy during the study.